https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:23:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/bxrishon9oa-car-t-therapy-for-aggressive-b-cell-lymphomas/ Thu, 08 Oct 2020 14:08:15 +0000 http://13.40.107.223/video/bxrishon9oa-car-t-therapy-for-aggressive-b-cell-lymphomas/ Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, discusses the use of CAR T-cell therapies for patients with aggressive B-cell lymphomas, including tisagenlecleucel and axicabtagene ciloleucel, both approved by the FDA in the third-line setting for patients with aggressive B-cell lymphomas. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]> https://mirror.vjregenmed.com/video/x7rlj8ttv_o-state-of-the-art-in-car-t/ Thu, 08 Oct 2020 14:08:15 +0000 http://13.40.107.223/video/x7rlj8ttv_o-state-of-the-art-in-car-t/ Peter A. Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an outlook in the current CAR-T climate and where things are moving in the future, including a better understanding of response, T-cell exhaustion and CD19 antigen loss. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

]]>